ViCentra, a Dutch MedTech startup, has secured €72.4 million in a Series C funding round. HealthTech Ventures led the investment, supporting the company's growth initiatives. Consequently, this capital injection will scale production of ViCentra's Kaleido insulin patch pump.
Scaling Kaleido Insulin Pump Production
The Utrecht-based company focuses on advanced diabetes management solutions. Its Kaleido pump offers a discreet and user-friendly option for insulin delivery. Indeed, the device aims to improve the quality of life for individuals with diabetes.
This funding enables ViCentra to expand its market reach.
Furthermore, the company competes in a dynamic sector alongside established players like Insulet and Medtronic. ViCentra's technology represents a significant advancement in medical devices.
Moreover, the investment also included participation from BioMed Capital and Innovate Europe. This financial backing will accelerate product development and commercialization efforts. ViCentra continues to innovate within the digital health landscape.